Masimo (NASDAQ:MASI) and Vaso (OTCMKTS:VASO) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, profitability and dividends.
Institutional and Insider Ownership
82.9% of Masimo shares are owned by institutional investors. 11.5% of Masimo shares are owned by company insiders. Comparatively, 9.1% of Vaso shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Masimo has a beta of 1.14, suggesting that its stock price is 14% more volatile than the S&P 500. Comparatively, Vaso has a beta of 0.61, suggesting that its stock price is 39% less volatile than the S&P 500.
This table compares Masimo and Vaso’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings & Valuation
This table compares Masimo and Vaso’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Masimo||$858.29 million||9.35||$193.54 million||$3.03||49.63|
|Vaso||$73.98 million||0.05||-$3.73 million||N/A||N/A|
Masimo has higher revenue and earnings than Vaso.
This is a summary of current recommendations for Masimo and Vaso, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Masimo currently has a consensus price target of $160.50, indicating a potential upside of 6.72%. Given Masimo’s higher possible upside, analysts plainly believe Masimo is more favorable than Vaso.
Masimo beats Vaso on 11 of the 11 factors compared between the two stocks.
Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry. It also provides Masimo rainbow SET platform that includes rainbow SET Pulse CO-Oximetry products that noninvasively monitor hemoglobin species, including oxygen saturation, pulse rate, perfusion index, pleth variability index, and respiration rate from the pleth; noninvasively monitor hemoglobin concentration, and carboxyhemoglobin and methemoglobin; monitor arterial oxygen saturation and acoustic respiration rate; and calculates oxygen content and oxygen reserve index. In addition, the company offers SedLine brain function monitoring technology to measure the brain's electrical activity by detecting EEG signals; capnography and gas monitoring products comprising external plug-in-and-measure capnography and gas analyzers, integrated modules, and handheld capnograph and capnometer devices; and O3 regional oximetry for tissue oxygen saturation measurement. Further, it provides Patient SafetyNet, a surveillance, remote monitoring, and clinician notification solution; MyView, a wireless presence-detection system; and connectivity devices. Additionally, the company offers Trace, a patient data visualization and reporting software that monitors Masimo Root and Radical-7. The company provides its products directly, as well as through distributors and original equipment manufacturers partners to hospitals, emergency medical service providers, physician offices, long term care facilities, veterinarians and consumers. Masimo Corporation was founded in 1989 and is headquartered in Irvine, California.
Vaso Corporation operates in the healthcare equipment and information technology industries in the United States and internationally. The company operates through three segments: IT, Professional Sales Service, and Equipment. The IT segment primarily focuses on healthcare IT and managed network technology services. This segment offers managed diagnostic imaging applications, managed network infrastructure, managed network transport, and managed security services. The Professional Sales Service segment principally focuses on the sale of healthcare capital equipment for General Electric Healthcare (GEHC) into the health provider middle market. Its offerings include GEHC diagnostic imaging capital equipment, GEHC service agreements, and GEHC and third party financial services. The Equipment segment primarily focuses on the design, manufacture, sale, and service of proprietary medical devices. This segment provides Biox series Holter monitors and ambulatory blood pressure recorders; ARCS series analysis, reporting, and communication software for physiological signals, such as ECG and blood pressure; MobiCare multi-parameter wireless vital-sign monitoring systems; and Enhanced External Counterpulsaion therapy systems that are used for non-invasive, outpatient treatment of ischemic heart disease, as well as in-service and training support. The company was formerly known as Vasomedical, Inc. and changed its name to Vaso Corporation in November 2016. Vaso Corporation was founded in 1987 and is headquartered in Plainview, New York.
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.